Recently, two prospective studies of patients with advanced HCC who received ICIs reported that patients with high baseline AFP levels had a higher frequency of immune-related liver injury and significantly higher levels of inflammation markers than patients with normal AFP levels (142). Here, AFP is linked to hepatocellular carcinoma.